Ramón Morillo Verdugo,1 Esther Ramírez Herráiz,2 Raquel Fernández-Del Olmo,3 Montserrat Roig Bonet,4 María Valdivia García51Valme University Hospital, Seville, Spain; 2La Princesa University Hospital, Madrid, Spain; 3Market Access Department, Roche Farma, S.A., Madrid, Spain; 4Project Department, Technical Advisory of Projects and Innovation “Esclerosis Múltiple España”, Madrid, Spain; 5Fundación de Esclerosis Múltiple Madrid, Madrid, Spain Purpose: Adherence to disease-modifying treatments is essential in order to maximize the beneficial effects of treatment for multiple sclerosis (MS). There are numerous treatments that have been approved. Treatment selectio...
Alberto Riñon1, Mandy Buch2, Derek Holley2, Elisabetta Verdun11Merck Serono S.A. &nda...
Background: Multiple Sclerosis (MS) is a debilitating disease of the central nervous system. Usually...
Journal Article; Research Support, Non-U.S. Gov't;BACKGROUND Adherence to interferon β-1b (INFβ-1b)...
Adherence to disease-modifying treatments is essential in order to maximize the beneficial effects o...
Background and Aims: In multiple sclerosis (MS), non-adherence/non-persistence is related to subopti...
Introduction. Multiple sclerosis is an inflammatory demyelinating disease of the central nervous sys...
Aleksandra Kołtuniuk, Joanna Rosińczuk Department of Nervous System Diseases, Faculty of Healt...
WOS: 000444552800005PubMed ID: 30138155Background: Adherence to medication treatment in patients wit...
Background: Adherence to interferon b-1b (INFb-1b) therapy is essential to maximize the beneficial e...
Adherence to interferon β-1b (INFβ-1b) therapy is essential to maximize the beneficial effects of tr...
Danny Decoo,1 Mathieu Vokaer2 1Department of Neurology and Neurorehab, AZ Alma, Sijsele, Belgium; 2...
Adherence to interferon β-1b (INFβ-1b) therapy is essential to maximize the beneficial effects of tr...
Michael Munsell,1 Molly Frean,1 Joseph Menzin,1 Amy L Phillips2 1Boston Health Economics, Inc., Wal...
Luis Lizán,1 Marta Comellas,1 Silvia Paz,1 José Luis Poveda,2 Dennis M Meletiche,3 Car...
Introduction: The objective of this work was to assess the factors identified in the Global Adherenc...
Alberto Riñon1, Mandy Buch2, Derek Holley2, Elisabetta Verdun11Merck Serono S.A. &nda...
Background: Multiple Sclerosis (MS) is a debilitating disease of the central nervous system. Usually...
Journal Article; Research Support, Non-U.S. Gov't;BACKGROUND Adherence to interferon β-1b (INFβ-1b)...
Adherence to disease-modifying treatments is essential in order to maximize the beneficial effects o...
Background and Aims: In multiple sclerosis (MS), non-adherence/non-persistence is related to subopti...
Introduction. Multiple sclerosis is an inflammatory demyelinating disease of the central nervous sys...
Aleksandra Kołtuniuk, Joanna Rosińczuk Department of Nervous System Diseases, Faculty of Healt...
WOS: 000444552800005PubMed ID: 30138155Background: Adherence to medication treatment in patients wit...
Background: Adherence to interferon b-1b (INFb-1b) therapy is essential to maximize the beneficial e...
Adherence to interferon β-1b (INFβ-1b) therapy is essential to maximize the beneficial effects of tr...
Danny Decoo,1 Mathieu Vokaer2 1Department of Neurology and Neurorehab, AZ Alma, Sijsele, Belgium; 2...
Adherence to interferon β-1b (INFβ-1b) therapy is essential to maximize the beneficial effects of tr...
Michael Munsell,1 Molly Frean,1 Joseph Menzin,1 Amy L Phillips2 1Boston Health Economics, Inc., Wal...
Luis Lizán,1 Marta Comellas,1 Silvia Paz,1 José Luis Poveda,2 Dennis M Meletiche,3 Car...
Introduction: The objective of this work was to assess the factors identified in the Global Adherenc...
Alberto Riñon1, Mandy Buch2, Derek Holley2, Elisabetta Verdun11Merck Serono S.A. &nda...
Background: Multiple Sclerosis (MS) is a debilitating disease of the central nervous system. Usually...
Journal Article; Research Support, Non-U.S. Gov't;BACKGROUND Adherence to interferon β-1b (INFβ-1b)...